Device for detecting and/or determining the concentration of an analyte present in a tissue and a method and use of this device
11536651 · 2022-12-27
Assignee
Inventors
Cpc classification
G01N2021/458
PHYSICS
A61B5/444
HUMAN NECESSITIES
International classification
A61M5/32
HUMAN NECESSITIES
A61B5/00
HUMAN NECESSITIES
Abstract
The device for detecting and/or determining the concentration of an analyte present in a tissue includes a sensor which is an optical fibre interferometer, and one interferometer arm being coated with an immobilised binding agent enabling selective binding of the analyte. The interferometer arm is mounted inside a guide enabling puncturing the tissue and performing an in situ measurement without the necessity to collect or prepare a sample. The guide is provided with a closed guide face, longitudinal perforations on sidewalls enabling the analyte to reach the binding agent, and an opening in the input end of the guide for introducing the interferometer with the arm into the guide. At the input end, the opening is sealed, enabling the isolation of the interior of the guide from the surroundings. The interferometer is mounted in a position in which the interferometer does not touch the inside walls of the guide.
Claims
1. A device for presence and concentration of an analyte present in a tissue, comprising: a sensor being comprised of an interferometer, wherein said interferometer comprises an optical fiber arm, having a fiber arm axis, and a binding agent being coated on the arm so as to enable a selective binding of an analyte present in a tissue; and a guide having an input end, a contact end opposite said input end, and a guide axis, wherein said guide is comprised of: a sidewall being between said input end and said contact end and defining an interior, a closed guide face at said contact end, a plurality of longitudinal perforations on said sidewalls so as to enable the analyte to reach said binding agent through said guide, and an opening at said input end, said interferometer being centrally mounted within said guide through said opening without contacting said sidewall, said fiber arm axis being coaxial with said guide axis, said opening being sealed so as to isolate said interior from surroundings except through said plurality of longitudinal perforations.
2. The device, according to claim 1, wherein said fiber arm axis is shifted relative to said guide axis by less than 100 μm.
3. The device, according to claim 1, wherein said interferometer is centrally mounted within said guide by epoxy glue.
4. The device, according to claim 3, wherein said epoxy glue is heat set to said interferometer and said guide by a temperature drop less than 10° C./s.
5. The device, according to claim 1, wherein said guide is comprised of metal.
6. The device, according to claim 1, wherein said guide has a guide length in a range of 0.5-30 cm, an internal diameter of 0.1 mm -5 mm, an external diameter of 0.2-7 mm, and a shape resembling a biopsy needle.
7. The device, according to claim 1, wherein said binding agent is comprised of at least one of a group consisting of: antibodies, antigen binding fragments, and antigen binding antibodies.
8. The device, according to claim 7, wherein said binding agent is selected for the analyte being a tumour marker or another disease marker so as to diagnose diseases or monitor treatment.
9. The device according to claim 8, wherein said binding agent is selected for the analyte being an HER2, PSA, AFP, CA19-9, CA125 or CEA tumour marker.
10. The device, according to claim 1, wherein said binding agent is comprised of a nucleic acid.
11. A method for an analyte, the method comprising the steps of: preparing a device, according to 1, wherein said interferometer further comprises a light source and a detector; emitting a light signal from said light source; detecting light waves from said optical fiber arm with said detector so as to determine a first interference pattern; contacting a tissue with said optical fiber arm so as to bind analyte in said tissue with said binding agent; emitting another light signal from said light source; detecting additional light waves from said optical fiber arm so as to determine a second interference pattern; determining a spectral shift between said first interference pattern and said second interference pattern so as to detect presence of the analyte in said tissue; determining a size of said spectral shift so as to detect a quantitative measure of the analyte in said tissue; and recording said presence and said quantitative measure.
12. The method, according to claim 11, wherein the step of contacting said tissue with said optical fiber arm is comprised of the step of: puncturing a sample of said tissue with said closed guide face.
13. The device, according to claim 1, said optical fiber arm having an optical fiber arm length, wherein said interferometer further comprises another optical fiber arm, having another optical fiber arm length, and wherein a difference between said optical fiber arm length and said another optical fiber arm length ranges from 5 to 100 μm.
Description
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
DETAILED DESCRIPTION OF THE INVENTION
Examples
Example 1. A Sensor for Detecting an Analyte
Example 1A
(11) In a preferred embodiment presented in
(12) The signal from the light source 1 is delivered to the circulator 3, from which it is subsequently delivered to the coupler 4 by single-mode pieces of optical fibre. The signal behind the coupler 4 is split into two optical fibers-interferometer arms (optical fiber arm 5 having fiber arm axis 5a, another optical fiber arm 5c). The signal is reflected from optical fiber faces, one of the arms 5 being coated with antibodies (binding agent 5b). The signal returns through the coupler 4 to the circulator 3, from which it is further led into the detector 2.
(13) The interferometer arm whose end is not coated is longer by ΔL=38.9 μm.
(14) One of the interferometer arms is coated with antibodies, which in this particular case is immunoglobulin G (IgG) from rabbit serum. These antibodies enable the detection of an antigen, which in this particular case is anti-rabbit immunoglobulin (obtained as a result of placing rabbit IgG in goat's blood plasma and separating the antigen) tagged with a luminescent marker FITC (Anti-IgG-FITC). Interference fringes in the wavelength domain, whose shift indicates the binding of antigens with antibodies, are visible on the detector.
(15) The process of coating a piece of optical fibre with antibodies was conducted according to the method presented below. The coated end of the optical fibre was submerged in a solution of NaOH with a concentration above 1 M for 10 min., and subsequently rinsed in purified water and dried in the air for 15 min. It was then kept for hours in a temperature of 90° C. in a 10% solution of (3-glycidyloxypropyl)trimethoxysilane (GOPS) with water (volume fraction) with pH=2, established by means of a 1 M solution of HCl. Subsequently, the tip of the optical fibre was rinsed in ethanol, upon which it was dried for 13 h in a temperature of 105° C. in vacuum or in an argon atmosphere. Subsequently, it was submerged in a 100 mg/ml solution of 1,1′-carbonyldiimidazole (CDI) in acetonitrile (ACN) for 20 min., upon which it was rinsed in acetonitrile and a solution of phosphate buffer (PBS) and incubated in a 1.2 mg/ml solution of PBS comprising the antibodies of immunoglobulin G from rabbit serum for 4 days in a temperature of 4° C., upon which it was stored in a solution of PBS for 12 h in a temperature of 4° C.
(16) In order to perform the measurement, the device is brought into contact with the sample, so that the analyte present in the sample could be bound with the binding agent.
(17)
(18) Calculation of the optical thickness of layers bound in an interferometer system:
LIST OF REFERENCES
(19) λ1—The wavelength at which a spectral minimum occurs before an increase in the thickness of the layers λ2—The wavelength at which a spectral minimum occurs after an increase in the thickness of the layers ϕ—Light phase for the given wavelength upon passing through the optical system Lp—Initial interferometer imbalance length np—The refractive index of the material ensuring the initial interferometer imbalance ΔL—change in the length of the material at the face of the interferometer nΔ—The refractive index of the material which is the increasing material
(20) The minimum before the growth (increase) of the layers is considered to be the initial light phase ϕ1. After the growth of the optical thickness of the layer, the same phase condition ϕ2 will be fulfilled for another wavelength. Such a condition can be written down as:
(21)
Assuming
φ.sub.1=φ.sub.2
We obtain
(22)
(23) Due to this, the following dependence can be reached after transformations:
(24)
(25) This dependence describes the change in the physical length of the layer which was bound in the system. More detailed explanations involving the calculation method can also be found in Hariharan, P. (2007). Basics of Interferometry. Elsevier Inc.
Example 1B
(26) In an alternative, preferred embodiment presented in
(27) The signal from the light source 1 is delivered to the coupler 4 via optical fibres. The signal behind the coupler 4 is split into two optical fibres—interferometer arms. The signal is reflected from the optical fibre faces, one of the arms 5 being coated with antibodies. The signal returns through the coupler 4 to the detector 2.
(28) The interferometer arm whose end is coated is longer by ΔL=10 μm.
(29) One of the interferometer arms is coated with antibodies, which in this particular case is immunoglobulin G (IgG) from rabbit serum. These antibodies enable the detection of an antigen, which in this particular case is anti-rabbit immunoglobulin (obtained as a result of placing rabbit IgG in goat's blood plasma and separating the antigen) tagged with a luminescent marker FITC (Anti-IgG-FITC). Interference fringes in the wavelength domain, whose shift indicates the binding of antigens with antibodies, are visible on the detector.
(30) The process of covering one of the interferometer arms with antibodies consisted of several steps. The optical fibre was first degreased by means of isopropyl alcohol in order to remove contaminants. Subsequently, the optical fibre was submerged in distilled water and boiled for 15 minutes. Upon removal from water, the optical fibre was placed in a 2% solution of (3-mercaptopropyl)trimethoxysilane (MPTS) in toluene. After 30 minutes the optical fibre was removed and rinsed in toluene, and subsequently submerged in a solution of N-succinimidyl 4-20 maleimido-butyrate (GMBS, no. CAS 8-307-12-6) with a concentration of 6 mg/10 ml of ethanol with a concentration of 96%. The optical fibre was kept in this solution for 60 minutes. It was subsequently rinsed once in ethanol and three times in distilled water. The optical fibre was later placed in a solution of antibodies with a concentration of 1 mg/ml in a solution of phosphate buffer. The coated optical fibre was removed from the solution after 12 hours and rinsed in distilled water.
(31)
Example 1C
(32) In a preferred embodiment presented in
(33) The signal from the light source 1 is delivered to the splitter 6. The signal behind the splitter 6 is split into two optical fibres—interferometer arms. The signal propagates through the interferometer arms, whose different lengths ensure the initial imbalance of the interferometer. One of the optical fibres comprises a break 9 in the middle of its length, and the ends on both sides of the break 9 are placed at a distance of 0.1 mm from each other. Through the coupler 7 the signal enters the optical spectrum analyser 8.
(34) One of the tips of the cut optical fibre is coated with antibodies like in Example 1A, which in this particular case is immunoglobulin G (IgG) from rabbit serum. These antibodies enable the detection of an antigen, which in this particular case is anti-rabbit immunoglobulin (obtained as a result of placing rabbit IgG in goat's blood plasma and separating the antigen) tagged with a luminescent marker FITC (Anti-IgG-FITC). The coated end of the optical fibre has been moved back to the second tip at the same distance as before.
(35) The measurement is performed by contacting the coated end of the optical fibre with the studied sample, so that the analyte could by bound by the binding agent.
(36) Interference fringes in the wavelength domain, whose shift by 0.5 nm indicates the binding of an antigen layer with a thickness of 115 nm with antibodies, are visible on the detector (
Example 1D. Coating with Affibodies
(37) In a preferred embodiment presented in
(38) The signal from the light source 1 is delivered to the circulator 3, from which it is subsequently delivered to the coupler 4 by single-mode pieces of optical fibre. The signal behind the coupler 4 is split into two optical fibres—interferometer arms. The signal is reflected from the optical fibre faces, one of the arms 5 being coated with affibodies. The signal returns through the coupler 4 5 to the circulator 3, from which it is further led into the detector 2.
(39) The interferometer arm whose end is not coated is longer by ΔL=38.9 μm.
(40) In the case of the affibodies, immobilisation by means of thiol groups is applied using the available reagents (Thermofisher Scientific, Waltham, Mass.). To this end, the end of the interferometer is submerged in 1 M sulphuric acid for 1 h and subsequently rinsed with distilled water and submerged for 15 min in ethanol and for another 15 min in acetone. The cleaned end of the optical fibre is subsequently submerged in anhydrous acetone comprising 2% of APTES (3-aminopropyltriethoxysilane) for 0.5-5 min. Upon the end of the reaction, the optical fibre is rinsed in anhydrous acetone and dried in the air for 15-30 min. Subsequently, the optical fibre is incubated in a cross-linking buffer (50 mM of sodium phosphate, 0.15 M of NaCl, 10 mM of EDTA, pH 7.2) comprising 2 mg/ml of Sulfo-SMCC (sulphosuccinim idyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) for 1 h in room temperature. After rinsing in the cross-linking buffer and drying in the air for 30 min., the optical fibre is stored in 4° C. in a dessicator until the moment of incubation with the affibody.
(41) In order to reduce the terminal thiol groups, to a solution of affibody with a concentration of 1 mg/ml in a reducing buffer (50 mM of sodium phosphate, 150 mM of NaCl, 2 mM of EDTA, pH 7.5), DTT (dithiothreitol) is added to obtain the final concentration of 20 mM with a subsequent incubation for 1-2 hours in room temperature or for 45 min in 37° C. The surplus of DTT should be removed by column filtration, e.g. with Sephadex G-25, equilibrated with the cross-linking buffer. The collected eluent comprising the affibody with a reduced thiol group should be immediately used to modify the previously prepared optical fibre. To this end, the end of the optical fibre is incubated in a solution of the Affibody for 2-4 h in room temperature and subsequently rinsed by means of the cross-linking buffer and stored in a solution of physiological saline (PBS) in 4° C.
Example 2. The Device for Performing Measurements Directly in Tissue
(42) The interferometer according to Example 1A or 1B or 1C or 1D is placed in a metal guide 30 with a length ranging between 0.5 and 30 cm, an internal diameter of 0.1 mm-5 mm, an external diameter of 0.2-7 mm and a shape resembling a biopsy needle. The interferometer 10 is introduced through the opening 32 in the input end 34 of the guide and is attached to the input end 34 of the guide 30 by specialised epoxy glue, e.g. MULTIBOND-1101 from the MULTIBOND company, so that the surface of the interferometer does not touch the walls of the guide (like in
(43) Tests presenting the impact of sealing on attenuation/loss have been performed. The used measurement equipment:
(44) A set for the measurement and monitoring of the changes in insertion loss (insertion attenuation):
(45) The measurements used a device from the EXFO-IQ203 company integrated in a panel form, provided with:
(46) a laser source (IQ2123 ORL) with two wavelengths: 1310 nm+20/−25 nm and 1550 nm+10/−40 nm,
(47) with a spectral width of 45/65 nm (1310/1550 nm),
(48) with a temperature stability of 0.03 dB (t=8 h T=0 . . . 50° C., and
(49) an InGaAs (IQ1103) detector
(50) measurement range 800-1700 nm,
(51) relative precision of power measurement 0.015 dB,
(52) The results of the conducted tests are presented in Table 1 below:
(53) TABLE-US-00001 TABLE 1 The results of the studies of changes in insertion loss. A IL at airtight connections performed after the test Test results (The change in attenuation after the test should P.sub.in P.sub.out not exceed 0.2 dB for the criteria [|μW] [μW] of Telcordia GR1221) Sample [before [after A IL P-positive no. sealing] sealing] [dB] N-negative 1 5.373 5.342 0.00 P 2 6.338 6.338 0.00 P 3 6.695 6.679 0.01 P 4 6.203 6.177 0.02 P 5 6.811 6.790 0.01 P 6 6.510 6.513 0.00 P 7 6.708 6.709 0.00 P 8 6.614 6.613 0.00 P 9 6.844 6.834 0.01 P 10 6.371 6.359 0.01 P 11 5.831 5.827 0.00 P 12 5.750 5.755 0.00 P 13 6.227 6.231 0.00 P 14 6.285 6.275 0.01 P 15 6.502 6.488 0.01 P 16 5.968 5.945 0.02 P 17 6.281 6.285 0.00 P 18 6.330 6.324 0.00 P 19 6.480 6.451 0.02 P 20 6.524 6.520 0.00 P 21 6.174 6.173 0.00 P mean 0.01
(54) The interferometer attached to the input end of the guide ensures the ability to sterilise the sensor and ensures free inflow of the tested substance, and at the same time ensures keeping the optical fibre sensor at a distance from the guide walls, so that the movement of the guide does not affect the performed measurement. Such a method of attachment provides a barrier against the penetration of biological and chemical contaminants and substances which could disrupt the measurement.
(55) The guide 30 with guide axis 30a has a closed guide face 31 at a contact end 34a of the guide and longitudinal perforations 33 in sidewall 31a, enabling the analyte to reach the interferometer 10. The opening 32 in the input end 34 of the guide, constituting an entrance for the piece of optical fibre, of the interferometer 10 into the guide 30 is sealed, enabling a tight isolation of the interior 31b of the guide 30 from the surroundings.
(56) The device in this embodiment also comprises, besides the light source 1 and the detector 2, a monitor 21 and a printer 22.
Example 3. Measurement of the Concentration of the HER2 Tumour Marker
Example 3A. Measurement with Antibodies
(57) For the measurement of the HER2 tumour marker, a piece of optical fibre is prepared by immobilising the antibodies which selectively bind the HER2 tumour marker (anti-HER2 monoclonal antibodies, R&D Systems, Minneapolis, Minn.), as described in Example 1, the difference being that the binding agent is immunoglobulin selectively binding the HER2 tumour marker (anti-HER2 monoclonal antibodies, R&D Systems, Minneapolis, Minn.).
(58) The measurement of the concentration of the tumour marker is performed by introducing for 5 sec.-15 min. the optical probe described in Example 1A or 1B or 1C, placed inside a metal guide, as described in Example 2, into the tissue by direct puncturing therewith the tumour tissue in the patient's body (similar as during a diagnostic biopsy performed with a biopsy needle) or directly after cutting off the tumour or by submerging it in a tissue homogenate obtained by mechanical dispersion thereof. The concentration of the marker present in the tissue corresponds to the amount of markers bound to the surface of the interferometer, and the value of the concentration is determined based on the spectral shift.
Example 3B. Measurement with Affibodies
(59) The method for making an optical probe is different from the one from Example 3A in that instead of the antibodies, affibodies are immobilised using thiol groups, as described in Example 1D. The sensor is placed in the guide as described in Example 2. The measurement of a tumour marker, e.g. HER2, is performed similarly to Example 3A.
LIST OF REFERENCES
(60) 1—light source 2—detector 3—circulator 4—coupler 5—interferometer arm coated with a binding agent 6—optical power splitter 7—optical power splitter maintaining the polarity 8—optical spectrum analyser 9—break in the course of the optical fibre 10—interferometer 21—monitor 22—printer 30—guide 31—guide face 32—opening in the input end of the guide 33—perforations 34—input end of the guide